The abstract is read at the publisher; the summary is JClub's.
In adults with moderate-to-severe active thyroid eye disease, a 5-infusion 10 mg/kg veligrotug regimen produced markedly higher week-15 proptosis responder rates than placebo (70% vs 5% by Hertel).
- Why it matters: Active thyroid eye disease remains debilitating with unmet needs, motivating tests of targeted therapies that can improve eye symptoms and disease activity safely.
- What they did: In the global phase 3 THRIVE trial, adults with onset ≤15 months, proptosis ≥3 mm, and CAS ≥3 were randomized 2:1 to veligrotug or placebo every 3 weeks for 5 IV infusions, with efficacy assessed through week 52.
- The result: Week-15 responses favored veligrotug across endpoints (PRR by MRI/CT 71% vs 9%; ORR 67% vs 5%; diplopia improvement 59% vs 20%; resolution 49% vs 12%), and 70% of initial responders maintained proptosis response at week 52 with no serious treatment-related adverse events.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.